{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T23:01:20Z","timestamp":1793746880369,"version":"4.6.1"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.msard.2022.104114","type":"journal-article","created":{"date-parts":[[2022,8,14]],"date-time":"2022-08-14T17:35:32Z","timestamp":1660498532000},"page":"104114","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Risk factors associated with permanent disability in neuromyelitis optica spectrum disorders"],"prefix":"10.1016","volume":"68","author":[{"given":"Edgar R.","family":"Valdivia-Tangarife","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge I.","family":"Gamez-Nava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando.","family":"Cort\u00e9s-Enr\u00edquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario A.","family":"Mireles-Ram\u00edrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura.","family":"Gonzalez-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana M.","family":"Salda\u00f1a-Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5613-6682","authenticated-orcid":false,"given":"Miguel Angel.","family":"Mac\u00edas-Islas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.msard.2022.104114_bib0001","doi-asserted-by":"crossref","first-page":"S831","DOI":"10.1007\/s100720070021","article-title":"A prospective study on the prognosis of multiple sclerosis","volume":"21","author":"Amato","year":"2000","journal-title":"Neurolog. Sci."},{"issue":"10","key":"10.1016\/j.msard.2022.104114_bib0002","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1093\/brain\/awaa251","article-title":"Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis","volume":"143","author":"Amato","year":"2020","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.msard.2022.104114_bib0003","first-page":"57","article-title":"Infectious disease risk in the elderly","volume":"23","author":"Bender","year":"2003","journal-title":"Immunol. Allergy Clin."},{"issue":"5","key":"10.1016\/j.msard.2022.104114_bib0004","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1007\/s00415-020-09699-2","article-title":"Clinical features and prognosis of late-onset neuromyelitis optica spectrum disorders in a Latin American cohort","volume":"267","author":"Carnero Contentti","year":"2020","journal-title":"J. Neurol."},{"issue":"8","key":"10.1016\/j.msard.2022.104114_bib0005","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1177\/1352458513515085","article-title":"Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset","volume":"20","author":"Collongues","year":"2014","journal-title":"Multiple Sclerosis J."},{"issue":"2","key":"10.1016\/j.msard.2022.104114_bib0006","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s40120-019-0143-2","article-title":"Late onset of neuromyelitis optica spectrum disorders","volume":"8","author":"Fragoso","year":"2019","journal-title":"Neurology Therapy"},{"issue":"19","key":"10.1016\/j.msard.2022.104114_bib0007","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1212\/WNL.0000000000004611","article-title":"Prevalence and clinical features of neuromyelitis optica spectrum disorders in northern Japan","volume":"89","author":"Houzen","year":"2017","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.msard.2022.104114_bib0008","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1742-2094-9-14","article-title":"Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients","volume":"9","author":"Jarius","year":"2012","journal-title":"J. Neuroinflammation"},{"issue":"3","key":"10.1016\/j.msard.2022.104114_bib0009","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3390\/ijms17030273","article-title":"The immunology of neuromyelitis optica-current knowledge, clinical implications, controversies and future perspectives","volume":"17","author":"Jasiak-Zatonska","year":"2016","journal-title":"Int. J. Mol. Sci."},{"issue":"14","key":"10.1016\/j.msard.2022.104114_bib0010","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1212\/WNL.0b013e3182a6cb5c","article-title":"Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica","volume":"81","author":"Jiao","year":"2013","journal-title":"Neurology"},{"issue":"14","key":"10.1016\/j.msard.2022.104114_bib0011","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1177\/1352458516687403","article-title":"Predictors of response to first-line immunosuppressive therapy in neuromyelitis optica spectrum disorders","volume":"23","author":"Kim","year":"2017","journal-title":"Multiple Sclerosis J."},{"issue":"6","key":"10.1016\/j.msard.2022.104114_bib0012","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1093\/brain\/aws109","article-title":"Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan","volume":"135","author":"Kitley","year":"2012","journal-title":"Brain"},{"key":"10.1016\/j.msard.2022.104114_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102522","article-title":"Risk of relapse in patients with neuromyelitis optica spectrum disorder: recognition and preventive strategy","volume":"46","author":"Ma","year":"2020","journal-title":"Multiple Sclerosis Related Disord."},{"issue":"9","key":"10.1016\/j.msard.2022.104114_bib0014","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1001\/archneurol.2012.314","article-title":"Epidemiology of neuromyelitis optica in the United States: a multicenter analysis","volume":"69","author":"Mealy","year":"2012","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.msard.2022.104114_bib0015","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.msard.2018.12.011","article-title":"Long-term disability in neuromyelitis optica spectrum disorder with a history of myelitis is associated with age at onset, delay in diagnosis\/preventive treatment, MRI lesion length and presence of symptomatic brain lesions","volume":"28","author":"Mealy","year":"2019","journal-title":"Multiple Sclerosis Related Disord."},{"issue":"4","key":"10.1016\/j.msard.2022.104114_bib0016","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.coi.2010.06.011","article-title":"Immune memory and aging: an infinite or finite resource?","volume":"22","author":"Nikolich-\u017dugich","year":"2010","journal-title":"Curr. Opin. Immunol."},{"issue":"4","key":"10.1016\/j.msard.2022.104114_bib0017","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1136\/jnnp.73.4.429","article-title":"Optic neuromyelitis syndrome in Brazilian patients","volume":"73","author":"Papais-Alvarenga","year":"2002","journal-title":"J. Neurol. Neurosur. Psychiatry"},{"issue":"2","key":"10.1016\/j.msard.2022.104114_bib0018","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1212\/WNL.0000000000011153","article-title":"Worldwide incidence and prevalence of neuromyelitis optica: a systematic review","volume":"96","author":"Papp","year":"2021","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.msard.2022.104114_bib0019","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1055\/s-0039-3399505","article-title":"What you need to know about AQP4, MOG, and NMOSD","volume":"39","author":"Prasad","year":"2019","journal-title":"Semin. Neurol."},{"issue":"5","key":"10.1016\/j.msard.2022.104114_bib0020","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1007\/s00415-008-0781-2","article-title":"Characteristics of Devic's disease (neuromyelitis optica) in Mexico","volume":"255","author":"Rivera","year":"2008","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2022.104114_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103083","article-title":"Status of the neuromyelitis optica spectrum disorder in Latin America","volume":"53","author":"Rivera","year":"2021","journal-title":"Multiple Sclerosis Related Disord."},{"issue":"2","key":"10.1016\/j.msard.2022.104114_bib0022","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1001\/jamaneurol.2013.599","article-title":"Early relapses, onset of progression, and late outcome in multiple sclerosis","volume":"70","author":"Scalfari","year":"2013","journal-title":"JAMA Neurol."},{"issue":"13","key":"10.1016\/j.msard.2022.104114_bib0023","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1177\/1352458516685416","article-title":"Clinical characteristics of late onset neuromyelitis optica spectrum disorder: a multicenter retrospective study in Korea","volume":"23","author":"Seok","year":"2017","journal-title":"Multiple Sclerosis J."},{"issue":"6","key":"10.1016\/j.msard.2022.104114_bib0024","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000607","article-title":"Late-onset neuromyelitis optica spectrum disorder: the importance of autoantibody serostatus","volume":"6","author":"Sepulveda","year":"2019","journal-title":"Neurology-Neuroimmunology Neuroinflammation"},{"issue":"2","key":"10.1016\/j.msard.2022.104114_bib0025","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1212\/01.wnl.0000194259.90286.fe","article-title":"Disability progression in multiple sclerosis is slower than previously reported","volume":"66","author":"Tremlett","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2022.104114_bib0026","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1212\/WNL.53.5.1107","article-title":"The clinical course of neuromyelitis optica (Devic's syndrome)","volume":"53","author":"Wingerchuk","year":"1999","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.msard.2022.104114_bib0027","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","article-title":"The spectrum of neuromyelitis optica","volume":"6","author":"Wingerchuk","year":"2007","journal-title":"Lancet Neurol."},{"issue":"5","key":"10.1016\/j.msard.2022.104114_bib0028","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1212\/01.CON.0000389937.69413.15","article-title":"Neuromyelitis optica spectrum disorders","volume":"16","author":"Wingerchuk","year":"2010","journal-title":"Continuum"},{"issue":"2","key":"10.1016\/j.msard.2022.104114_bib0029","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.msard.2022.104114_bib0030","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1080\/00207454.2016.1254630","article-title":"Distinctive characteristics of early-onset and late-onset neuromyelitis optica spectrum disorders","volume":"127","author":"Zhang","year":"2017","journal-title":"Int. J. Neurosci."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822006216?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822006216?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:12:37Z","timestamp":1761901957000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034822006216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":30,"alternative-id":["S2211034822006216"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2022.104114","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk factors associated with permanent disability in neuromyelitis optica spectrum disorders","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2022.104114","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104114"}}